

## FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE STATEMENT

Page 1 of 7

ATTY. DOCKET NO.:  
CHL-102(C)SERIAL NO.:  
(TBD) 10/790,647

APPLICANT: LOHRAY, et al.

FILING DATE: March 1, 2004

GROUP: 1626

## US PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Issue Date	Name	Class	Sub Class	FILING DATE If Appropriate
BS	1.	5,089,514	02/18/92	Hulin	—	—	
	2.	5,306,726	04/26/94	Hulin	—	—	
	3.	5,985,884	11/16/99	Lohray, et al.	—	—	
	4.	6,048,883	4/11/2000	Haigh, et al.	—	—	
	5.	6,054,453	4/25/2000	Lohray, et al.	—	—	
	6.	6,130,214	10/10/2000	Lohray, et al.	—	—	
BS	7.	6,166,049	12/26/2000	Smith	—	—	

## FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No
BS	8.	EP 0753 298	01/15/97	Tsujita, et al.	—	—	.
	9.	EP 90 3343	03/24/99	Nagao, et al.	—	—	
	10.	WO 91/19702	12/26/91	Hulin	—	—	
	11.	WO 94/01420	01/20/94	Haigh, et al.	—	—	
	12.	WO 94/13650	06/23/94	Haigh	—	—	
	13.	WO 94/29302	12/22/94	Faller	—	—	
	14.	WO 95/03038	02/02/95	Goldberg, et al.	—	—	
	15.	WO 95/17394	06/29/95	Cantello, et al.	—	—	
	16.	WO 96/04260	02/15/96	Haigh	—	—	
	17.	WO 96/04261	02/15/96	Haigh	—	—	
	18.	WO 96/33998	10/31/96	Terasawa, et al.	—	—	
	19.	WO 97/25042	07/17/97	Smith	—	—	
	20.	WO 97/31970	09/04/97	Hammer, et al.	—	—	
	21.	WO 97/36579	10/09/97	Willson	—	—	
	22.	WO 98/02159	01/22/98	Poste, et al.	—	—	
	23.	WO 98/28534	07/02/98	Kim, et al.	—	—	
	24.	WO 99/08501	02/25/99	Lohray, et al.	—	—	
	25.	WO 99/16758	04/08/99	Lohray, et al.	—	—	
	26.	WO 99/19313	04/22/99	Lohray, et al.	—	—	
	27.	WO 99/20614	04/29/99	Lohray, et al.	—	—	
	28.	WO 99/38850	08/05/99	Lohray, et al.	—	—	
	29.	WO 00/23417	04/27/2000	Jeppesen, et al.	—	—	
	30.	WO 00/23445	04/27/2000	Jeppesen, et al.	—	—	
	31.	WO 00/23451	04/27/2000	Jeppesen, et al.	—	—	
BS	32.	WO 01/53257	07/26/2001	Lohray, et al.	—	—	

*Chantal Dacay*

110161009v1

21/2/07

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.: CHL-102(C)	SERIAL NO.: [TBD] 10 / 790,647
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		APPLICANT: LOHRAY, et al.	
Page 2 of 7		FILING DATE: March 1, 2004	GROUP: 1626

**OTHER ART**  
(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

33.		A. N. Collins, G. N. Sheldrake and J. Crosby, in "Chirality in Industry II", John Wiley & Sons, Inc., 1997, 81-98 and references therein
34.		Cancer Research, 58, 3344-3352 (1998)
35.		Carcinogenesis, vol. 19 no. 11, 1949-1953 (1998)
36.		Cell, 87, 377-389 (1996)
37.		Cell, 55, 932-943 (1999)
38.		Cell, 79, 1147-1156 (1994)
39.		Cell, 83, 803-812 (1995)
40.		Cell, 99, 239-242 (1999)
41.		Cell Biology, 95, 14751-14756 (1998)
42.		Current Biol., 5, 618-621 (1995)
43.		E. L. Eliel and S. H. Wilen, in "Stereochemistry of Organic Compound", John Wiley & Sons, Inc., 1994, 297-464 and references therein
44.		Endocrine Reviews, 20(5), 649-688 (1999)
45.		Endocrinology 135, 798-800 (1994)
46.		Exp. Clin. Endocrinol. Diabetes: 109(4), S548-559 (2001)
47.		T. W. Greene and P. G. M. Wuts "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., 1999, 3 <sup>rd</sup> Ed., 201-245 along with references therein
48.		J. Clin. Invest., 85, 962-967, 1990
49.		J. Medicinal Chemistry, 43(4), 527-550 (2000)
50.		Jaques et al. "Enantiomers, Racemates and Resolution", Wiley Interscience, 1981
51.		Knorr, L., Ber., 1885, 18, 299-311
52.		Macikinnon et al., J. Biol. Chem. 261, 2548-2552 (1986)
53.		Med. Res. Rev., 20(5), 350-366 (2000)
54.		Miller et al., Br. Med. J. 282, 1741-1744 (1981)
55.		Molecular Cell, 465-470 (1998)
56.		Nature Reviews: Drug Discovery: 1(4), 276-86 (2002)
57.		Nature, 405, 421-424 (2000)
58.		Paal C. Ber., 1885, 18, 367-371

*Mark Buckley*

*2/12/07*

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.:	SERIAL NO.:
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		CHL-102(C)	[TBD] 10/790,647
Page 3 of 7		APPLICANT: LOHRAY, et al.	
		FILING DATE: March 1, 2004	GROUP: 1626

es	59.	Petit D., Bonnefis M. T., Rey C. and Infante R., Effects of ciprofibrate on liver lipids and lipoprotein synthesis in normal and hyperlipidemic rats, Atherosclerosis, 74, 215-225 (1988)
	60.	Picardo et al., Arteriosclerosis, 6, 434-441 (1986)
	61.	Principles of Asymmetric Synthesis J E Baldwin Ed. Tetrahedron series, Volume 14, Page no. 311-316
	62.	Proc. Natl. Acad. Sci. 93, 5793-5796 (1996)
	63.	Proc. Natl. Acad. Sci., 94, 237-241 (1997)
	64.	Remington: the Science and Practice of Pharmacy, 19 <sup>th</sup> Ed., 1995
	65.	Ross and Glomset, New Engl. J. Med., 295, 369-377 (1976)
	66.	Science, 269, 543-46 (1995)
	67.	R. A. Sheldon, in "Chirotechnology", Marcel Dekker, Inc. NY, Basel, 1993, 173-204 and references therein
	68.	Stampfer et al., N. Eng. J. Med., 325, 373-381 (1991)
	69.	Trends Endocrine. Metabolism, 4, 291-296 (1993)
	70.	Trends in Pharmacological Sci., 469-473 (2000)
	71.	Trinder, P. Ann. Clin. Biochem. 1969. 6: 24-27
es	72.	Wieland, O. Methods of Enzymatic Analysis. Bergermeyer, H., O., Ed., 1963. 211-214

*Reinhart Sackey*

<b>FORM PTO-1449 (Modified)</b>		<b>ATTY. DOCKET NO.:</b> <b>CHL-102(C)</b>	<b>SERIAL NO.:</b> <b>[TBD] 10/750,647</b>
<b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT: LOHRAY, et al.</b>	
Page 4 of 7		<b>FILING DATE:</b> March 1, 2004	<b>GROUP:</b> 1626

#### US PATENT DOCUMENTS

Exam- Init	Ref Des	Document No.	Issue Date	Name	Class	Sub Class	FILING DATE If Appropriate
73.	5,861,173		01/19/1999	Nishioka , et al.			
74.	5,885,997		03/23/1999	Lohray , et al.			
75.	5,889,025		03/30/1999	Lohray, et al.			
76.	5,889,032		03/30/1999	Lohray , et al.			
77.	6,130,214		10/10/2000	Lohray , et al.			
78.	6,159,966		07/24/2001	Lohray, et al.			
79.	6,265,401		07/24/2001	Lohray , et al.			
80.	6,294,586		09/25/2001	Yelle , et al.			
81.	6,313,113		11/06/2001	Lohray , et al.			
82.	6,362,360		03/26/2002	Andersson , et al.			
83.	6,369,067		04/09/2002	Gurram , et al.			
84.	6,440,961		08/27/2002	Lohray , et al.			
85.	6,444,816		09/03/2002	Das , et al.			
86.	6,521,622		02/18/2003	Ricks , et al.			
87.	6,525,083		02/25/2003	Acton, III , et al.			
88.	6,569,901		05/27/2003	Mogensen , et al.			
89.	6,573,628		05/03/2003	Sloupensky , et al.			
90.	6,589,969		07/08/2003	Tajima , et al.			
91.	6,602,901		08/05/2003	Jeppesen , et al.			

#### FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes      No

*Chuck Buckley 21-2107*

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.: CHL-102(C)	SERIAL NO.: <u>TBD 10/790, 647</u>
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		APPLICANT: LOHRAY, et al.	
Page 5 of 7		FILING DATE: March 1, 2004	GROUP: 1626

**OTHER ART**  
**(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)**

92.		<i>DDT</i> , Vol. 6, No. 13, 2001, page 654-55, "Unravelling metabolic syndrome X."
93.		<i>Diabetes Mellitus - A Fundamental Text book</i> , pages 326-329, 611-613, "Definition and Classification of Diabetes Mellitus and the New Criteria for Diagnosis."
94.		<i>Am Heart J.</i> 1988 Dec; 116(6 Pt 2): 1713-24 "The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease."
95.		3rd Report of the National Cholesterol Education Program (NCEP), Expert Panel on 'Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)'- NIH, USA.
96.		<i>Diabetes Mellitus - A Fundamental Text book</i> , pages 326-329, 611 -613, "Fatty Acids and Insulin Resistance."
97.		<i>Ann NY Acad Sci.</i> 1999 Nov 18; 892:25-44, "Etiology of the metabolic syndrome : potential role of insulin resistance, leptin resistance, and other players."
98.		<i>Horm Metab Res.</i> 2003 Feb; 35(2); 92-96, "Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion."
99.		<i>Metabolism.</i> 2003 Jun; 52(6):713-9, "Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome."
100.		<i>The Journal of Clinical Endocrinology &amp; Metabolism</i> 2003, 88(5):2031-2036, "Glucose Intolerance, Insulin Resistance, and Hyperandrogenemia in First Degree Relatives of Women with Polycystic Ovary Syndrome."
101.		<i>Diabetes Care.</i> 2003 Jun; 26(6): 1752-8, "Type 2 Diabetes and Subsequent Incidence of Breast Cancer in the Nurses' Health Study."
102.		<i>Exp Biol Med (Maywood).</i> 2003 Apr; 228(4): 396-405, "Insulin resistance and its contribution to colon carcinogenesis."
103.		<i>Cancer Epidemiology, Biomarkers &amp; Prevention.</i> 2000 Dec.; 9:1271-79. "Possible Mechanisms Relating Diet and Risk of Colon Cancer."
104.		<i>Pol Arch Med Wewn.</i> 1998 Aug; 100(2):125-32, "Bone density in type 2 diabetes as related to obesity and adrenal function."
105.		<i>FEBS Lett.</i> 2000 Apr 7;471(1):119-24, "Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts."
106.		<i>Endocrinology</i> 1999; 140(11): 5060-65, "Thiazolidinediones inhibit osteoclast-like cell formation and bone absorption in vitro."

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.:	SERIAL NO.:
		CHL-102(C)	(TBD) 10/790,647
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		APPLICANT: LOHRAY, et al.	
Page 6 of 7		FILING DATE: March 1, 2004	GROUP: 1626

**OTHER ART**  
(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

CB	107.		<i>Am J Surg.</i> 1995 Jan; 169(1): 105-9, "Alterations in hepatocyte insulin binding in chronic pancreatitis : effects of pancreatic polypeptide."
	108.		<i>J Clin. Endocrinol. Metab.</i> 2001 May; 86(5): 2289-95, "Dyslipidemia in familial partial lipodystrophy caused by an R482W mutation in the LMNA gene."
	109.		<i>Clin Nephrol.</i> 2000 Nov; 54(5): 366-73, "Mild renal dysfunction is associated with insulin resistance in chronic glomerulonephritis."
	110.		<i>J Am Soc Nephrol.</i> 2002 Jul; 13(7): 1894-900, "Insulin Resistance as an Independent Predictor of Cardiovascular Mortality in Patients with End-Stage Renal Disease."
	111.		<i>Kidney Int.</i> 2002 Sep; 62(3): 963-70, "Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study."
	112.		<i>Aliment Pharmacol Ther.</i> 1999 Feb; 13(2): 209-17, "Glucose metabolism and insulin sensitivity in inactive inflammatory bowel disease."
	113.		<i>J Am Acad Dermatol.</i> 1985 Jul; 13(1): 1-30, "Xanthomas and hyperlipidemias."
	114.		<i>The Journal of Clinical Endocrinology &amp; Metabolism</i> 2003; 88(6):2422-2429, "The Potential Influence of Inflammation and Insulin Resistance on the Pathogenesis and Treatment of Atherosclerosis-Related Complications in Type 2 Diabetes."
	115.		<i>J Clin Endocrinol Metab</i> 2003; 88: 2412-2421, "The Metabolic Syndrome : Peroxisome Proliferator-Activated Receptor Y and Its Therapeutic Modulation."
	116.		<i>J Clin Pract Suppl.</i> 2003 Mar; (134):10-7, "Inflammation, the metabolic syndrome and cardiovascular risk."
	117.		<i>Cuff Drug Targets Cardiovasc Haematol Disord.</i> 2001 Dec; 1(2): 107-20, "Reduction and prevention of the cardiovascular sequelae of the insulin resistance syndrome."
	118.		<i>The Journal of Clinical Endocrinology &amp; Metabolism</i> 88(6):2399-2403, "Insulin Resistance/Compensatory Hyperinsulinemia, Essential Hypertension, and Cardiovascular Disease."
	119.		<i>Endocrinology</i> 2003; 144(6) 2201-2207, "Minireview : Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors."
	120.		<i>Am J Manag Care.</i> 2002 Dec; 8(20 Suppl):S635-53, "The metabolic syndrome, type 2 diabetes and cardiovascular disease : understanding the role of insulin resistance."
	121.		<i>Am J Health Syst Pharm.</i> 2002 Dec 1;59 Suppl 9:S9-13, "Treating dual defects in diabetes: insulin resistance and insulin secretion."
ES	122.		<i>Endocrinol Metab Clin North Am.</i> 2001 Dec;30(4):935-82, "Insulin therapy in type 2 diabetes."

*Brands-clay 21-2107*